ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
506 articles with ImmunoGen Inc.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 89,800 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
5/20/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference. The presentation is scheduled for June 2, 2021 at 9:30am ET.
-
ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
5/19/2021
ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status Results to be Presented in an Oral Session at 2021 ASCO Annual Meeting
-
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
5/10/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2021.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2021
5/3/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on April 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,900 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results
4/26/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, May 10, 2021 to discuss its first quarter operating results. Management will also provide a brief update on the business.
-
ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting
4/10/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that a poster highlighting preclinical data for its novel ADAM9-targeting ADC, IMGC936, which is being investigated in multiple solid tumor types, is being presented at the American Association of Cancer Research Virtual Annual Meeting April 10-15, 2021.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2021
4/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on March 31, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 29,500 shares of its common stock to two employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2021
3/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on February 26, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 66,500 shares of its common stock to two employees under the ImmunoGen, Inc.
-
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
2/24/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming H.C. Wainwright Virtual Global Life Sciences Conference.
-
ImmunoGen Reports Recent Progress and 2020 Financial Results
2/12/2021
ImmunoGen - Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End Full Approval Pathway for IMGN632 in BPDCN Aligned with FDA; Updated Phase 1/2 Data in BPDCN Presented at ASH Balance Sheet Funds Operations into the Second Half of 2022 Conference Call to be Held at 8:00 a.m. ET Today
-
ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare Conference
2/11/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming SVB Leerink 10th Annual Global Healthcare Conference. A webcast
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2021
2/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on January 29, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to two four employees under the ImmunoGen, Inc.
-
ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results
1/29/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its 2020 operating results.
-
As the 2021 virtual JP Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.
-
ImmunoGen Announced Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/4/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 91,800 shares of its common stock to two new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Indu
-
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
12/5/2020
Updated Data Demonstrating Favorable Safety Profile and Encouraging Monotherapy Activity in BPDCN Presented During Oral Session
-
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2020
12/1/2020
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on November 30, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 51,500 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
11/6/2020
Partnership with Huadong Medicine Accelerates Development and Commercialization of Mirvetuximab Soravtansine in Greater China Encouraging Anti-Tumor Activity and Tolerability Data from FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin ® in Platinum-Sensitive Ovarian Cancer Presented at ESMO FDA Breakthrough Therapy Designation Received for IMGN632 in Relapsed or Refractory BPDCN
-
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference
11/4/2020
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference.